Literature DB >> 12438246

An estrogen-responsive element-targeted histone deacetylase enzyme has an antiestrogen activity that differs from that of hydroxytamoxifen.

Ediz Demirpence1, Abdelhabib Semlali, Joan Oliva, Patrick Balaguer, Eric Badia, Marie-Josèphe Duchesne, Jean-Claude Nicolas, Michel Pons.   

Abstract

We showed previously that prolonged treatment of a MCF-7-derived cell line with hydroxytamoxifen (OHT) induces the irreversible silencing of some estrogen-responsive genes, whereas OHT-resistant cell growth appears simultaneously (E. Badia et al., Cancer Res., 60: 4130-4138, 2000). Based on the hypothesis that particular gene silencings could be involved in triggering the resistance phenomenon, we focused our study on the mechanism of OHT-induced silencing. More precisely, we wished to determine to what extent the recruited histone deacetylase (HDAC) activity, which is known to be involved in the repressive effect induced by antagonist ligands of nuclear receptors, could participate in various aspects of OHT effects, particularly in gene silencing. A fusion protein (HDAC-EG) of human HDAC1 fused with the estrogen receptor DNA-binding domain and the glucocorticoid receptor ligand-binding domain allowed targeting of chimeric HDAC1 activity on estrogen-responsive elements (EREs) in the presence of glucocorticoid ligands. When HDAC-EG was transiently expressed in HeLa cells together with estrogen receptor, an antiestrogen-like effect was obtained on an ERE-controlled luciferase reporter gene in the presence of agonist or antagonist glucocorticoids. In MCF-7-derived cells stably expressing HDAC-EG and an estrogen-regulated luciferase, liganded HDAC-EG again produced an antiestrogenic effect on expression of natural estrogen-regulated genes such as pS2, progesterone receptor, and cathepsin D and cell growth together with chimeric luciferase gene expression. However, a prolonged HDAC-EG-mediated antiestrogen effect did not lead to irreversible luciferase gene silencing, as OHT does. It nevertheless accelerated the OHT-driven phenomenon. The antiestrogen effect of OHT thus differs from that of an ERE-targeted HDAC1 activity that might participate in irreversible silencing but is not sufficient to trigger it.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12438246

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  5 in total

Review 1.  The Interactome of the Glucocorticoid Receptor and Its Influence on the Actions of Glucocorticoids in Combatting Inflammatory and Infectious Diseases.

Authors:  Ioanna Petta; Lien Dejager; Marlies Ballegeer; Sam Lievens; Jan Tavernier; Karolien De Bosscher; Claude Libert
Journal:  Microbiol Mol Biol Rev       Date:  2016-05-11       Impact factor: 11.056

Review 2.  Tamoxifen resistance and epigenetic modifications in breast cancer cell lines.

Authors:  Eric Badia; Joan Oliva; Patrick Balaguer; Vincent Cavaillès
Journal:  Curr Med Chem       Date:  2007       Impact factor: 4.530

Review 3.  Glucocorticoids, Sex Hormones, and Immunity.

Authors:  Oxana Bereshchenko; Stefano Bruscoli; Carlo Riccardi
Journal:  Front Immunol       Date:  2018-06-12       Impact factor: 7.561

4.  Protein Kinase C α Modulates Estrogen-Receptor-Dependent Transcription and Proliferation in Endometrial Cancer Cells.

Authors:  Alicia M Thorne; Twila A Jackson; Van C Willis; Andrew P Bradford
Journal:  Obstet Gynecol Int       Date:  2013-06-17

5.  Silencing MED1 sensitizes breast cancer cells to pure anti-estrogen fulvestrant in vitro and in vivo.

Authors:  Lijiang Zhang; Jiajun Cui; Marissa Leonard; Kenneth Nephew; Yongquan Li; Xiaoting Zhang
Journal:  PLoS One       Date:  2013-07-30       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.